Sidelines, it is still too expensive to buy right now although if all goes well $5 down the line is quite possible. Word to the wise, the last time delcath really stood out as a good buy could be seen as 2009.

History of some kind is going to happen here

The revenue climb wall is tough and uncertain and lengthy, I see that fundamentally. OM is tiny to begin with. Excessive dreaming has allowed this stinky company to stay in business.

That does not rule out a fun market cap down the line. All you have to do is visit June 2017 to know behind all the misery, money loves to chase drama

you actually are being idealistic on that. Idealism is 2nd fiddle, I don't even on big stock trading know what the company does in some cases

Kind of you to say. I think retail holders will make out okay at this price if offering holders plan to deliver. It is just theory by all as I see unpredictability

20 million shares outstanding and fully funded and an overhang of 40 million or more to be executed in 2019, probably Nasdaq and a Roth analyst putting a price target, the final shoe update on phase 3 in 2nd half of year. This is if offering holders are not just shady game players

In that scenario, $5 price target for mid to late 2019

How to tell shady from sunny. The closer that $20 million could be raised quickly, the closer to sunny. That is as scientific as it gets

I dispute that the fast gigantic drop last time was primarily caused by shorts.

Good things can happen here. People are blinded by the convertible. This is uncharted territory, for now I like the upcoming $2.00 to $2.50 range.

always darkest before dawn but since I am open minded (it is also darkest before it gets darker)

It seems on the surface most are close minded, don't count on it all cases, the watch list is full. Offering the great unknown

I still believe significant shorting is the great myth

Nobody knows beyond current stock price until an offering is actually completed.

Open minded people will watch with interest. The x factor offering holders voted for this exact scenario whoever they may be and why

I might but I will limit the risk to $3000 until there is a completed offering

She cares about getting $20 million, that is the solid gold here. I think the previous was kind of silly, apparently it was a throw a way if it could not be done at par 1 cent, my thoughts

For whatever reason faked out by the offering description given 3 weeks ago, tra la la la

Sometimes when everybody else is fearful, it is time to be brave, not just yet, not certainly, but yes maybe

My concern is strictly limited to how these offerings go. If they exceed expectations, we will probably go back to Nasdaq. But the company could run out of money, don't see how that would please anybody.

If I am surprised by some kind of change of control, analysis starts all over

A shaky struggling company likely has more ethics issues than the average company. A convertible is particularly questionable, but the company was not going to just cease operations.

For that very reason, solid clear evidence should be demanded by all, otherwise it is a cesspool of improperly directed fear and loathing. I don't mind suspicion in all things but this board is over the line

I am my own investment analyst here. The message board is garbaged up badly. Company is struggling, I don't see anything made clear beyond that.

First thing to acknowledge is after June, bad decisions to be in this stock. The convertible was taking the stock down about 25 to 35 percent daily for a time in November, etc.. Before June was terrible too. Just a tragedy, not everything is about ethics. What a destruction of a thought process to turn it into ethics this and ethics that

The part most relevant to your post is Stoll and Simpson can be seen on an equal footing as to knowing about everything. Also he is buddies with Dr. Pedder. Stoll has a very long history in medical.

Also annual report makes claim that Simpson is very highly qualified clinically. That flies in the face of how this message board mostly thinks

Audit fees for SEC filers averaged $1.5 million, with a median audit fee of $402,812.

I assume base pay and bonus structure for delcath is within the bell curve for similar type companies as described.

It all really comes back to the convertible makes ugly look super ugly.

I am using the term corruption loosely. Legally a company with difficulties probably skates close to the edge.

As an investor I only care about these offerings, that is the immediate future. Only buy when you see the whites of their eyes

If one of the 3 is corrupt, then all 3 would share the burden and other bod members too, If they accept one penny for their services, they have some responsibility.

I would say they are all corrupt in paying out bonus money given stock performance, but it is a slippery slope. If stock value was down 55 percent year over year, should there be bonus money considerations.

Specifics would be over bonus questions, although if her primary duty is clinical, the record is okay. Huge loss of value contradicts clinically phase 3 is at least limping forward.

People want to blame Simpson because of convertible

I noticed Stoll served on St Jude Medical and he is more responsible than Simpson for financial aspects of company

So the one that is sitting on the sidelines during some recent rough periods is delusional or ...?

Not a promise by any means, but if it happens it means close minded trapped themselves, that is if they like poker no limits. Right now Trompete is steam rolling opposition

Transition back to Nasdaq, that will be big and could be the plan

Trompete is a tough customer. In one corner Trompete, in the other shadowy Nasdaq hope

Can't imagine management is worried about the topic. They could have started reverse split process sooner. 3 weeks, a long time since vote and offering plan was laid out, we are hanging without knowledge

Don't believe anybody that says management does not care. Management cares a lot about money. Think money, it is a key to any company

Funny how little talk about the offering, almost like it is not there. Company silence on the offering is deafening, so all real thinking is head scratching on how these offerings will play

If it goes up 10 fold in 2 or 3 weeks, that would be true. June of 2017 was such a rarity though as well as a false signal in that case. I highly doubt May 2018 will perform like June 2017

Fortunately the modrica/trompete crowd are at least right in the short run, too early is dangerous and there is no definition for the right time

Simultaneous 1) she fooled us 2) she withheld press releases to support price 3) she stated phase 3 is not likely to be approved before 2020, how dare she fool us with an honest sounding assessment

Allies with none, that is my independence. Simpson is only useful to me if I make money. Nothing more emotional than "she let us lost money", that shoe is not mine

Those who paid attention to July filing saved money, those that treated the filing as hollow lost money. Same with the filing this year announcing planned vote for RS.

It is a fact that those two filings were very useful. There was no ruse to the vote for RS, they got their YES vote. Shadowy terms work better when the facts back the shadowy claim

These are 2 key situations where investors had a path to safety, since only some react while many others delay

One can question everything. It was hard to be a victor, but if you make a mistake, you pay and pay big.

The famous July filing was pertinent and all I needed. The company was at the mercy of shareholder support, without it as was the case, the avoidance of bankruptcy was a minor miracle

It is sad that so many believe the massive drop was something management had control over. Unacceptable analysis rules on this message board, I will say often.

On the other hand, investors always have a choice with their money.

It is so factual that part one of the convertible was highly destructive, one should have been fully wary in latter half of 2017. That is true history

There was one publically known offer as I recall by investors since 2013. It is not known if the offer was legit or a pump and dump. I think it was fake, there is no getting around the company was far from profit.

It is still unknown how far this technology could be from profit. If ICC is the answer, profitably could still be more than 7 years away. If will take a long time must be assumption for ICC trial and a 295 patient trial and submission is not free.

Company has been under the gun since 2013, clinicals take too long, Europe is casual, making their own filter is expensive for a no revenue company.

My belief is the risk/reward equation was bad, smart investors stayed away, and the rest of us have paid a price. My mistake, I own it

Risk/reward though is subject to change

I will worry about a legitimate company that is as always in the corner when faced with financing. BOD members are a known quantity out there being around as such are

Hard headed don't acknowledge that little biotechs with high salaries, which are nowhere near cash positive sounds commonplace.

There is no merit to making this about salary. 99 percent of mindset came out of a convertible that boggles the mind.

But in the real world the long suffering market cap and the large cash burn are a deadly duo. The cash burn is likely to climb given status of clinicals.

Talk real fundamentals or talk about shadowy shadows or calling folks Joanna